Cellectis SA (CLLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $118.86M
Last updated: Nov 17, 2026 at 10:55 AM ET
Cellectis SA (CLLS) Competitors
The companies most similar to Cellectis SA are Zentalis Pharmaceuticals Llc (ZNTL), Cartesian Therapeutics (RNAC) and Compass Therapeutics (CMPX). By market cap, Cellectis SA ranks 9th of the 13 companies on this page; Galectin Therapeutics (GALT) is the largest at $307.59M.
Peer Comparison
CLLS's ROIC of -74.1% is below the peer median of -46.7%, and its revenue growth of -85.4% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Zentalis Pharmaceuticals Llc (ZNTL) | $167.05M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cartesian Therapeutics Inc. (RNAC) | $193.69M | N/A | 179.8x | 0.0% | 147.2% | -92.9% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| enGene Therapeutics Inc. (ENGN) | $161.51M | N/A | N/A | 0.0% | -42.2% | 0.0% | 0.00% |
| Codexis Inc (CDXS) | $127.13M | N/A | N/A | -21.8% | N/A | 124.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Equillium Inc (EQ) | $106.20M | N/A | 29.3x | 0.0% | N/A | -52.3% | 0.00% |
| Genelux Corporation Common Stock (GNLX) | $84.38M | N/A | N/A | 0.0% | N/A | -95.3% | 0.00% |
| PDS Biotechnology Corp (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| Greenwich Lifesciences Inc (GLSI) | $219.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Galectin Therapeutics Inc (GALT) | $307.59M | N/A | N/A | 0.0% | 671.1% | 0.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Peer median | $147.55M | N/A | 29.5x | 0.0% | -46.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Cellectis SA, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Zentalis Pharmaceuticals Llc (ZNTL) | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment... | ZNTL competitors |
| Cartesian Therapeutics Inc. (RNAC) | Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs... | RNAC competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| enGene Therapeutics Inc. (ENGN) | enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery... | ENGN competitors |
| Codexis Inc (CDXS) | Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California. | CDXS competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Equillium Inc (EQ) | Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory... | EQ competitors |
| Genelux Corporation Common Stock (GNLX) | Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering... | GNLX competitors |
| PDS Biotechnology Corp (PDSB) | PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. | PDSB competitors |
| Greenwich Lifesciences Inc (GLSI) | Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /... | GLSI competitors |
| Galectin Therapeutics Inc (GALT) | Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic... | GALT competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
Frequently Asked Questions About CLLS
Who are Cellectis SA's main competitors?
The companies most similar to Cellectis SA include Zentalis Pharmaceuticals Llc (ZNTL), Cartesian Therapeutics (RNAC), Compass Therapeutics (CMPX), enGene Therapeutics (ENGN) and Codexis (CDXS), listed from the closest match.
Who is Cellectis SA's biggest competitor?
Galectin Therapeutics (GALT) is the largest of the similar companies at $307.59M; Zentalis Pharmaceuticals Llc (ZNTL) is the closest match by business profile, size, sector and industry.
How does CLLS stock compare with its competitors?
CLLS' P/S is 1.8x against a peer median of 29.5x; its net margin is 0.0% against a peer median of 0.0%.
Which of Cellectis SA's competitors pays a higher dividend?
Cellectis SA pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Cellectis SA bigger than its competitors?
No. Cellectis SA is 9th by market cap among the 13 companies on this page; the largest is Galectin Therapeutics (GALT) at $307.59M.
CLLS pages: Overview, Earnings, Forecast, Financials, Competitors